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Abstract
The acquisition of cellular invasiveness by breast epithelial cells and subsequent transition from ductal carcinoma
in situ (DCIS) to invasive breast cancer is a critical step in breast cancer progression. Little is known about the
molecular dynamics governing this transition. We have previously shown that overexpression of the transcriptional
regulator TBX3 in DCIS-like cells increases survival, growth, and invasiveness. To explore this mechanism further
and assess direct transcriptional targets of TBX3 in a high-resolution, isoform-specific context, we conducted
genome-wide chromatin-immunoprecipitation (ChIP) arrays coupled with transcriptomic analysis. We show that
TBX3 regulates several epithelial–mesenchymal transition (EMT)-related genes, including SLUG and TWIST1.
Importantly, we demonstrate that TBX3 is a direct regulator of SLUG expression, and SLUG expression is required
for TBX3-induced migration and invasion. Assessing TBX3 by immunohistochemistry in early-stage (stage 0 and
stage I) breast cancers revealed high expression in low-grade lesions. Within a second independent early-stage
non-high-grade cohort, we observed an association between TBX3 level in the DCIS and size of the invasive focus.
Additionally, there was a positive correlation between TBX3 and SLUG, and TBX3 and TWIST1 in the invasive
carcinoma. Pathway analysis revealed altered expression of several proteases and their inhibitors, consistent with
the ability to degrade basement membrane in vivo. These findings strongly suggest the involvement of TBX3 in the
promotion of invasiveness and progression of early-stage pre-invasive breast cancer to invasive carcinoma through
the low-grade molecular pathway.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Tumorigenesis within the breast is thought to involve
advancement through distinct stages, from benign
ductal epithelial hyperplasia to atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), and,
ultimately, invasive and metastatic carcinoma [1]. It is
estimated that approximately 25–50% of DCIS will
progress to invasive carcinoma during the lifetime of the
patient, generating potentially life-threatening disease

[2]. Clinical management of patients with DCIS usually
consists of surgical resection with additional radiation
therapy for most patients [3,4]. Several recent studies,
however, have suggested that a subset of patients with
early-stage (non-high-grade) DCIS do not benefit from
either surgery alone or combined surgery and radiation,
raising concern regarding overtreatment of this subpopulation [2,5,6]. Paradoxically, we are currently limited
in our ability to identify patients with DCIS who have an
intrinsically higher risk of local and invasive recurrence,

© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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such that there is also a risk of undertreatment if excision
is incomplete or radiation therapy is omitted.
The 21T series cell lines have been proposed as a
unique experimental model of breast cancer progression
[7]. Three cell lines were isolated from a single patient
and stably represent distinct stages of progression: 21PT
cells mimic ADH (non-tumorigenic); 21NT cells mimic
DCIS (tumorigenic and non-metastatic); and 21MT-1
cells mimic invasive mammary carcinoma (tumorigenic
and metastatic) in xenograft experiments [7,8]. We have
conducted extensive characterization of these cell lines
[8]. Importantly, we found that during the transition from
the clonally related DCIS-like 21NT cells to invasive
21MT-1 cells, TBX3 was within the list of clinically
relevant up-regulated transcripts [8].
TBX3 is a member of the T-box family of transcription factors involved in development [9]. TBX3
levels are up-regulated in several cancers, with most
of the literature focusing on breast cancer [8,10–12]
and melanoma [13,14]. Due to alternative splicing, two
TBX3 isoforms exist: TBX3iso1 and TBX3iso2.
TBX3iso2 contains an additional 20-amino acid
sequence in the DNA binding domain attributed to
the 2a exon, which TBX3iso1 lacks. Differing expression of TBX3 isoforms has been reported in several
breast cancer cell lines [12] and there is controversy
as to whether the two isoforms have unique functions [12,15,16]. Accumulating evidence suggests that
TBX3-mediated transcriptional repression of p14ARF
[11,17] and/or p21CIP1 [16,18] plays a role in driving
cancer progression through bypassing cellular senescence. Recent work has begun to identify a link between
TBX3 and epithelial-to-mesenchymal transition (EMT)
[19], with direct down-regulation of E-cadherin [13].
These findings are important, as an EMT phenotype
has been associated with the acquisition of migratory
and invasive properties, suppression of senescence
and apoptosis, and therapeutic resistance [20]. SLUG
(encoded by the SNAI2 gene) is a member of the SNAIL
family of transcription factors and a key mediator in
the promotion of EMT [20,21]. Specifically, SLUG has
been shown to trigger the initial phases of the EMT
process [22].
In this study, we explored the role of TBX3 in breast
cancer progression pathways, focusing specifically
on its involvement in the induction of EMT and the
transition from DCIS to invasive carcinoma. Immunohistochemical analysis revealed that TBX3 levels are
elevated in low-grade, pre-invasive DCIS with an associated invasive component, and significantly correlated
with the size of the invasive focus. Using genome-wide
bioinformatic approaches along with more conventional
in vitro studies, we have identified SLUG and TWIST1
as downstream targets of TBX3 and have assessed their
levels by immunohistochemistry in two independent
patient cohorts. Our findings suggest that TBX3 facilitates the process of early invasion in DCIS by promoting
the induction of EMT and tumor progression through
the low-grade pathway, as described by Bombonati
and Sgroi [23]. Finally, we propose a progression
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model in which SLUG is an important and necessary
effector downstream of TBX3, leading to increased
motility and induction of key invasiveness-associated
genes.

Materials and methods
Cell lines and culture conditions
The 21T series cell lines (21NT and 21MT-1) were
obtained as a gift from Dr Vimla Band [7]. 21T
series cell lines underwent authentication testing by
IDEXX Radil (IDEXX Bioanalytics, Missouri, CA,
USA; Case No 20250-2013). Cells were maintained in
αMEM media supplemented with 2 mM L-glutamine,
1 μg/ml insulin, 12.5 ng/ml EGF, 2.8 μM hydrocortisone, 10 mM HEPES, 1 mM sodium pyruvate, 0.1 mM
non-essential amino acids, 50 μg/ml gentamycin sulfate,
and 10% FBS (αHE10F). All reagents were obtained
from Wisent Inc (Saint-Jean-Baptiste, QC, Canada).
Stable 21NT transfectants previously generated [24]
were maintained in αHE10F medium supplemented
with 500 μg/ml G418 as a selection marker. Stable
lentiviral transductants were maintained in αHE10F
medium supplemented with either 0.8 μg/ml puromycin
(TBX3 knockdown lines) or 500 μM hygromycin
(SLUG knockdown lines) as a selection marker. Details
related to the generation of cell lines are located in
the supplementary material, Supplementary materials
and methods.
Cell lines representing other molecular breast cancer subtypes were purchased from ATCC (Manassas,
VA, USA). Cell lines were maintained in their respective media: T47D (RPMI), SKBR3 (McCoy’s 5A),
and MDA-MB-468 (αMEM), each supplemented with
10% FBS.

In vitro and in vivo characterization of cell lines
Detailed protocols related to western blots, immunofluorescence staining, migration assays, Transwell invasion
assays, chick choriallantoic membrane (CAM) assays,
gelatin zymography, cell–cell adhesion assay, and in
vitro gelatin degradation assays [25] are located in the
supplementary material, Supplementary materials and
methods.

Genomic and transcriptomic analyses
Detailed protocols related to qRT-PCR, chromatin
immunoprecipitation (ChIP), RNA-Seq (GEO Accession Number: GSE126153), ChIP promoter arrays
(GEO Accession Number: GSE126154), and the bioinformatics analyses [26] may be found in the supplementary material, Supplementary materials and methods.

Patient characteristics and immunohistochemistry
study
Patients with early-stage breast cancer were identified from the London Breast Cancer Database on the

© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd
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basis of having either DCIS only (stage 0) or DCIS
with an associated invasive component (stage I;
≤ 2 cm, and either pN0 or pN0mi). Cohort 1 consisted of 186 patients with low-, intermediate- or
high-grade DCIS with no invasion or early invasion
(stage 0 or stage I). Cohort 2 consisted of 118 patients
with non-high-grade DCIS with the aforementioned
characteristics, with either no invasion or early invasion (stage 0 or stage I). Clinicopathological variables
for cohort 1 and cohort 2 patients entered into this study
are listed in Table 1. There was no overlap between
patients in cohort 1 and cohort 2. The study was
conducted under a protocol approved by the Western
University Health Sciences Research Ethics Board
and the Clinical Research Impact Committee of Lawson Health Research Institute. Immunohistochemical
staining was conducted using the following antibodies: TBX3 (Abcam, Cambridge, MA, USA; ab99302;
1/200), SLUG (Abcam; ab27568; 1/750), and TWIST1
(Abcam; ab50887; 1/750). Details relating to immunohistochemistry protocol and quantification methods are
located in the supplementary material, Supplementary
materials and methods.

Results
TBX3 overexpression is associated with an invasive
and EMT phenotype
To examine the role of TBX3 in breast cancer,
non-invasive 21NT cells (which endogenously express
low levels of TBX3) were stably transfected with either
an empty vector, TBX3iso1 or TBX3iso2. Structural
differences between TBX3 isoforms are shown in the
supplementary material, Figure S1. Isoform specific
up-regulation was confirmed at the mRNA level using
isoform-specific primers, in addition to up-regulation
of total TBX3 protein levels (Figure 1A,B and supplementary material, Figure S2A). Functionally,
up-regulation of either TBX3 isoform led to an increase
in migration (supplementary material, Figure S3A).
TBX3-overexpressing cells also exhibited reduced
cell-to-cell adhesion in vitro (supplementary material,
Figure S3B). In the presence of calcium ions (+ CaCl2 )
or after adding increasing doses of EDTA to chelate
free calcium, there were reduced levels of cell-to-cell
adhesion, implying that several cell-adhesion molecules
may be involved (not solely Ca2+ -dependent cadherins). Loss of E-cadherin has been associated with
the switch to an EMT phenotype [23]. Additionally,
TBX3 is able to directly down-regulate E-cadherin in
melanoma lines [13]. We confirmed a down-regulation
of E-cadherin protein levels by immunofluorescence, as
well as decreased membrane localization with TBX3
overexpression (supplementary material, Figure S3C).
In order to assess the aggressiveness of the cell lines
in an in vivo system, we employed the chick embryo
chorioallantoic membrane (CAM) model. Fluorescently
labeled cells were injected into the vasculature of chicks
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Table 1. Clinicopathologic variables for patients entered into
Cohort 1 and Cohort 2

Characteristic
Total
Age (years)
≤ 50
> 50
Associated invasion
No invasion
Micro-invasion
Invasion
Histological type of invasive cancer
Total cases with invasion
NST
NST with lobular features
NST with tubular features
NST with mucinous features
NST with micropapillary features
Invasive lobular carcinoma
Invasive tubular carcinoma
Invasive mucinous carcinoma
IMC histologic grade
Total cases with invasion
Low
Intermediate
High
DCIS nuclear grade
Total cases with DCIS
Low
Low + intermediate
Intermediate
High
Hormone receptor status*
ER-positive
PR-positive
HER2-positive
Recurrence
No recurrence
Yes recurrence
Invasive recurrence
Non-invasive recurrence
Unknown
Micro-metastasis

Cohort 1
No of
patients (%)

Cohort 2
No of
patients (%)

186 (100)

118 (100)

17 (9.1)
169 (90.9)

14 (11.9)
104 (88.1)

100 (53.8)
12 (6.5)
74 (39.8)

84 (71.2)
2 (1.7)
32 (27.1)

74 (100)
55 (74.3)
9 (12.2)
3 (4.1)
3 (4.1)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)

34 (100)
26 (76.5)
3 (8.8)
3 (8.8)
0 (0.0)
0 (0.0)
0 (0.0)
1 (2.9)
1 (2.9)

74 (100)
26 (35.1)
36 (48.6)
12 (16.2)

34 (100)
16 (47.1)
18 (52.9)
0 (0.0)

100 (100)
10 (10.0)
0 (0.0)
41 (41.0)
49 (49.0)

118 (100)
16 (13.6)
44 (37.3)
58 (49.2)
0 (0.0)

66/82 (80.5)
52/71 (73.2)
16/57 (28.1)

33/34 (97.1)
29/34 (85.3)
3/34 (8.8)

162 (87.1)
13 (7.0)
10 (76.9)
3 (23.1)
11 (5.9)
8 (4.3)

118/118 (100)
0 (0.0)

NST, no special type; IMC, invasive mammary carcinoma; DCIS, ductal carcinoma
in situ; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal
growth factor receptor 2.
*Only available for patients with IMC.

at embryonic day 12 and cell extravasation was assessed
as previously described [27] (Figure 1C). Overexpression of either TBX3 isoform in 21NT cells resulted in an
increase in extravasation within the CAM. Extravasation
rates were drastically reduced with shRNA-mediated
knockdown of total TBX3 in invasive 21MT-1 cells,
which natively express TBX3 at high levels (levels
shown in supplementary material, Figure S2B–D). To
confirm that the cells are better able to exit the vasculature (and are not simply better able to survive
at T = 24 h), we performed live functional invadopodia assays within the CAM using confocal microscopy.
Six hours after injecting fluorescently labeled cells
into the CAM vasculature, a binary quantification of
invadopodia formation was conducted (Figure 1D). An

© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd
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Figure 1. TBX3 overexpression is associated with an invasive and EMT phenotype. (A) Total TBX3 protein levels were assessed by western
blot in 21NT transfectant cells. (B) Total TBX3, TBX3iso1, and TBX3iso2 transcript levels were assessed by RT-qPCR in 21NT transfectant cells,
normalized to GAPDH levels, and depicted as fold change relative to the empty vector control. Means derived from three biological replicates
were used during analysis. (C, D) Assessment of cell extravasation and functional invadopodia formation in vivo in the chick chorioallantoic
membrane (CAM) model. Green (CMFDA) fluorescently labeled cells were injected into the vasculature of the CAM (50 000 cells each),
and the vasculature was labeled red with lectin-rhodamine at T = 0. For cell extravasation, cells were counted 24 h post-injection in a 1
cm2 area across 30 biological replicates. For functional invadopodia formation, a binary quantification of in vivo invadopodia formation
was conducted 6 h post-cell injection. Cells were deemed positive for invadopodia formation when they possessed protrusions from the
vasculature into the stroma. Values reported represent the percentage of cells displaying functional invadopodia in vivo across six biological
replicates consisting of approximately 30 scanned cells each. (E) In vitro invadopodia formation assay for assessment of local cell invasion.
Cells were added to red fluorescently labeled gelatin and incubated for 12–24 h (as optimized) to allow for substrate degradation. Cells
were visualized using labelled phalloidin for identification of cellular F-actin cores at sites of local matrix degradation, signifying the
presence of invadopodia. Percentage of cells forming invadopodia was quantified from four biological replicates, assessing invadopodia
formation in 10–20 random, non-overlapping fields. (F, G) Protein levels of EMT markers by western blot. Protein samples were separated
by 10% SDS-PAGE and quantified by densitometry. Protein levels were normalized to vinculin, which served as the loading control for all
proteins aside from MMP9 (*secreted protein); in the latter case, MMP9 levels in the conditioned media samples were normalized to total
protein per lane based on Ponceau staining of the membrane. Where quantification of western blots is shown, data were acquired through
densitometric quantifications across three biological replicates. *p < 0.05; **p < 0.01; ***p < 0.001 by one-way ANOVA with Tukey’s post
hoc test for comparison between three groups, and Student’s t-test for comparison between two groups. Error bars represent standard
deviation.

increase in functional invadopodia was observed with
overexpression of TBX3 in 21NT cells. Furthermore,
the presence of functional invadopodia was reduced
with TBX3 knockdown in 21MT-1 cells. Representative
images for CAM experiments are shown in the supplementary material, Figure S4. Changes in invadopodia
formation rates were also verified using a standard in
vitro invadopodia formation assay (Figure 1E and supplementary material, Figure S5).

More invasive phenotypes were also observed
using transient transfections of TBX3iso1 or
TBX3iso2 into T47D (luminal A; ER+ /PR+ /HER2− ),
SKBR3 (HER2-enriched; ER− /PR− /HER2+ ), and
MDA-MB-468 (basal-like; ER− /PR− /HER2− ) breast
cancer cell lines, representing different molecular
subtypes (supplementary material, Figure S6A–C).
Collectively, this suggests that these findings have
broad applicability and are not cell type-specific.

© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd
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The functional alterations associated with TBX3
isoform overexpression suggest a more invasive EMT
phenotype. We examined the expression of several
EMT markers and observed alterations in multiple proteolytic enzymes and their inhibitors (MMP9, MMP14,
PLAU up-regulated; CST6 down-regulated), as well as
EMT-associated transcription factors (TWIST1, SLUG
up-regulated) with TBX3 overexpression (Figure 1F,G).
This was also observed (to a lesser extent) in shTBX3
cell lines (supplementary material, Figure S7A,B). We
observed an increase in the levels of active MMP2,
as assayed by gelatin zymography (supplementary
material, Figure S7C), indicating functional activation
of pathways involved in substrate degradation and
invasiveness.

TBX3 overexpression leads to an alteration
of mesenchymal transcript levels and direct
up-regulation of SLUG
To examine transcriptional changes associated
with TBX3 isoform overexpression and elucidate
the mechanisms involved, RNA-Seq was conducted
for TBX3iso1- and TBX3iso2-overexpressing cell
lines. Pathway analysis indicated that the top predicted functional changes for the TBX3 transfectants
include alterations in cellular movement, cellular
growth and proliferation, cell death, cell survival,
and cancer-associated processes (Figure 2A). Enrichment analysis (Enrichr) was conducted, with the input
list consisting of genes significantly altered (> 1.5-fold
up or down, FDR < 0.05) for cells overexpressing either
TBX3iso1 or TBX3iso2 relative to the control. Comparison to the Jensen TISSUES expression database
of large-scale tissue expression profiles revealed mesenchymal genes as most enriched (Figure 2B). Relative
to the control, we detected alterations in a large proportion of EMT-related genes compiled from the dbEMT
database [28] (Figure 2C).
To determine whether the TBX3-dependent changes
in gene expression are direct, chromatin immunoprecipitation (ChIP) experiments were conducted using
either TBX3 antibody or rabbit IgG antibody as a
non-specific control, and immunoprecipitated DNA
was hybridized to Affymetrix Promoter 1.0R arrays.
Using this approach, we identified 5652 and 5512
specific binding sites for TBX3iso1 and TBX3iso2,
respectively. Comparison of TBX3 binding sites with
our expression analysis identified 194 genes that were
directly regulated by both TBX3 isoforms (> 1.5-fold
up or down, FDR < 0.05) (Figure 2D and supplementary
material, Table S1). These 194 genes were analyzed
using the PANTHER database. The lowest P value and
corrected FDR statistic corresponded to the protease
inhibitor protein class (supplementary material, Figure
S8). Several other protein classes related to EMT were
also altered, including extracellular matrix proteins,
metalloproteases, and serine protease inhibitors. Importantly, within this list of 194 genes directly induced
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by TBX3 was SNAI2 (which encodes SLUG), a transcriptional regulator and potent inducer of EMT, which
may provide a mechanism for the previously described
EMT and invasion-associated functional changes in
TBX3-transfected cells.
Both TBX3 isoforms were shown to bind near an
intron/exon junction of SNAI2 based on the ChIP-array
data (Figure 2E). TBX3 has previously been shown to
bind to the consensus T-box binding element (TBE) in
several different contexts [29]. Consensus TBEs were
investigated using the JASPAR database of transcription factor binding sites (Figure 2E and supplementary material, Figure S9A–C). A highly conserved TBE
was found within the SNAI2 gene region that coincides
with binding of both TBX3 isoforms in the ChIP-array
dataset (supplementary material, Figure S7A,B). We
conducted ChIP qPCR validation using primers spanning this identified TBE. Published primer sequences
were used for the transcription start site (CDH1 TSS)
and coding region (CDH1 coding) of E-cadherin [13],
representing positive and negative controls, respectively
(Figure 2F). With TBX3 overexpression, there was a 3to 4-fold enrichment of TBX3 protein bound to the conserved TBE of SNAI2. Interestingly, this binding region
overlaps with a DNase I hypersensitive region and RNA
polymerase II binding region, which is suggestive of
open and transcriptionally active chromatin (Figure 2E).

SLUG up-regulation by TBX3 is essential
for increased migration and invasion
Given the strong evidence of SLUG involvement in the
induction of EMT [20,21], we proceeded to investigate whether SLUG was essential for the phenotypes
observed with TBX3 overexpression. SLUG levels were
knocked down in 21NT control and TBX3 transfectant
cell lines using stable shRNA-mediated lentiviral transduction (Figure 3A,B). The scramble control (SCR)
cells overexpressing either TBX3iso1 or TBX3iso2 had
higher rates of migration and invasion relative to the
empty vector control, similar to the levels that we previously reported in these cell lines [24]. With SLUG
knockdown, the rates of migration and invasion of TBX3
isoform transfectants were reduced to baseline levels,
despite expressing high levels of TBX3 (Figure 3C,D).
A large proportion (7/10) of our list of EMTand invasion-associated genes previously assessed
in this study were still significantly altered with
high TBX3 isoform expression in cells with SLUG
knockdown (Figure 3E,F). However, the induction of several key invasiveness-associated genes
up-regulated by TBX3 was significantly impaired in
the absence of SLUG, including MMP14, vimentin,
and fibronectin (Figure 3E,F). Importantly, these findings suggest that there are TBX3-induced changes
in expression of EMT-related genes that are both
SLUG-dependent and SLUG-independent, and that the
SLUG-dependent changes are required (although not
necessarily sufficient) for TBX3-induced migration
and invasion.

© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd
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Figure 2. TBX3 overexpression leads to an alteration of mesenchymal transcript levels and direct up-regulation of SLUG. RNA-Seq of total
mRNA from 21NT + EV, 21NT + TBX3iso1, and 21NT + TBX3iso2 cells in duplicate. (A) Pathway analysis was conducted using all output
RNA-Seq data for TBX3iso1- and TBX3iso2-overexpressing cells and compared with the empty vector control. (B) Enrichment analysis
was conducted for genes significantly altered (fold change > 1.5, FDR < 0.05). Results comparing resultant RNA-Seq profiles with the
Jensen TISSUES dataset and lowest P-value tissue sites are shown. (C) Heat map of EMT genes. The dbEMT database was used to compile
a list of 377 EMT genes and hierarchical clustering was conducted of RNA-Seq data. Duplicate samples are shown for each cell line.
(D) Chromatin immunoprecipitation (ChIP) experiments were conducted with TBX3 antibody or rabbit IgG. Datasets from RNA-Seq and
ChIP-array experiments were integrated to examine the effects of TBX3 isoform binding on gene transcript levels (all fold-change > 1.5,
FDR < 0.05). (E) RNA-Seq reads across the SNAI2 (SLUG) gene for 21NT + EV, 21NT + TBX3iso1, and 21NT + TBX3iso2 cell lines are shown
in the top three lines, followed by the identified TBX3 ChIP-array binding site. Highly conserved T-box binding elements (TBEs) in SNAI2 are
shown. DNAse I hypersensitivity and RNA polymerase II binding sites are shown in the bottom two lines. (F) ChIP experiments with TBX3
antibody or rabbit IgG control. Relative amounts of immunoprecipitated DNA were assessed by qPCR. E-cadherin (CDH1) coding region
and transcription start site (TSS) were used as negative and positive controls, respectively. The SNAI2 primers span both the predicted
overlapping TBE site identified in silico and the binding site from ChIP-array experiments. Values shown represent input-adjusted, IgG
control subtracted values for the specific TBX3 IP normalized to the empty vector control. Means derived from four biological replicates
were used during analysis. *p < 0.05; **p < 0.01; ***p < 0.001 by one-way ANOVA with Tukey’s post hoc test for comparison between three
groups. Error bars represent standard deviation (SD).

TBX3 expression is elevated in low-grade,
hormone-receptor-positive invasive breast cancers
and associated precursor lesions
From our initial characterization of effects mediated by TBX3iso1 and TBX3iso2, we observed

identical EMT-related functionality, including induction
of SLUG and TWIST1 expression. We then extended
our studies to human patient samples, assessing total
nuclear-localized TBX3 by immunohistochemistry
(supplementary material, Figure S10) across two patient
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Figure 3. SLUG up-regulation by TBX3 is essential for increased migration and invasion. (A) Western blot showing knockdown of SLUG
protein in shRNA transductants. Protein levels were normalized to vinculin as the loading control. (B) SNAI2 transcript levels were assessed
by RT-qPCR, normalized to RPLP0 levels, and depicted as fold-change relative to the empty vector control. (C, D) Migration and invasion
assays were conducted using 8.0 μm pore Transwells coated with either gelatin (migration) or Matrigel (invasion). Cells were allowed to
migrate or invade for 22 h. The number of cells that migrated or invaded per high power field is shown. Means are derived from four
biological replicates. (E) Protein levels of EMT and invasion-associated genes were assessed by western blot, normalized to vinculin. (F)
mRNA levels of several EMT and invasion-associated genes evaluated by RT-qPCR, normalized to RPLP0 transcript levels, and depicted as
fold-change relative to the empty vector shScramble control (+ EV + SCR). Means derived from three biological replicates were used during
analysis. *p < 0.05; **p < 0.01; ***p < 0.001 by either one-way ANOVA with Tukey’s post hoc test or two-way ANOVA with Tukey’s post hoc
test for comparison within and between sub-groups, respectively. Error bars represent standard deviation.

cohorts (Table 1). Our first cohort consisted of 186
pre-invasive (stage 0, DCIS only) and early invasive
breast cancer (IMC; invasive mammary carcinoma,
stage I) patient samples, where we used an antibody that
recognizes both TBX3 isoforms. We examined four subpopulations of cells, including benign non-columnar,
benign columnar, DCIS, and invasive cancer, after
observing high expression of TBX3 in benign columnar
cells (Figure 4A). Earlier studies based on genome
sequencing data and mutational association suggest that
columnar cell lesions (CCLs; which include columnar
cell change, columnar cell hyperplasia, and flat epithelial atypia) may be an early morphologic indicator
of propensity for, or a non-obligate precursor to, the
development of breast cancer [30,31]. We confirmed an
association between TBX3 and estrogen receptor (ER)
and progesterone receptor (PR) expression in invasive
breast cancers (Figure 4B,C), which has been suggested
by previous studies [32]. TBX3 positivity was highest
in low- and intermediate-grade DCIS and significantly
lower in high-grade DCIS (Figure 4D). We then examined a second independent patient cohort of 118 patients
with non-high-grade (low- and intermediate-grade)
DCIS, with or without associated early invasive cancer
(stage 0 and stage I), for increased power in evaluation
of TBX3 association with invasiveness of low-grade

breast cancers. In this second cohort, nuclear TBX3
expression in the DCIS was associated with the size of
the invasive focus (p < 0.001) (Figure 4E).
We then conducted immunohistochemical staining
for the EMT transcription factors SLUG and TWIST1
(which were directly and indirectly up-regulated by
TBX3, respectively) in our second patient cohort.
TWIST1 was exclusively nuclear localized, and SLUG
was predominantly nuclear with occasional cytoplasmic staining (Figure 4A and supplementary material,
Figure S11). Each marker was assessed in all four
cell populations in the same manner as for TBX3. We
identified a positive correlation between TBX3 and both
SLUG (p < 0.05) and TWIST1 (p < 0.001) expression
in the invasive component (Figure 4F,G). Additionally, both SLUG and TWIST1 were up-regulated in
CCLs, and SLUG levels were significantly higher in
low-grade (grade 1) DCIS relative to both grade 1 + 2
(mixed) and grade 2 DCIS (Figure 4H), exhibiting
staining patterns similar to TBX3. Collectively, these
results suggest that TBX3 may be facilitating the
process of early invasion even at the earliest stages
of progression (i.e. CCLs, DCIS), and offer potential
roles for downstream EMT-related proteins such as
SLUG and TWIST1 in the invasiveness of early-stage
breast cancer.
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Figure 4. TBX3 expression is elevated in low-grade, hormone-receptor-positive invasive breast cancers and associated precursor lesions.
Patient samples representing cohort 1 were immunohistochemically stained and assessed for nuclear TBX3, and cohort 2 samples were
stained and assessed for nuclear TBX3, SLUG, and TWIST1. (A) Representative staining patterns of cohort 2 samples (TBX3 expression
and staining patterns were similar in cohort 1; not shown). (B–D) Nuclear TBX3 in cohort 1, consisting of 186 patients with early-stage
breast cancer (all nuclear grades) identified from the London Breast Cancer Database as having either DCIS only (stage 0) or DCIS with an
associated early invasive component (stage I; ≤ 2 cm, and either pN0 or pN0mi). Nuclear TBX3 was compared across ductal epithelial cell
types (benign non-columnar, benign columnar, DCIS, and invasive mammary carcinoma). The association between TBX3 and (B) estrogen
receptor (ER), (C) progesterone receptor (PR), and (D) DCIS nuclear grade is shown. (E–H) Nuclear TBX3, SLUG, and TWIST1 in cohort 2,
consisting of 118 patients with non-high-grade (nuclear grade 1 or 2) DCIS, with or without associated early invasive cancer (stage 0 or
stage I). Levels were compared across ductal epithelial cell types and clinical data. (E) Correlation analysis for nuclear TBX3 and size of the
invasive focus in patients with stage I breast cancer. (F, G) Correlation analysis of TBX3/SLUG and TBX3/TWIST1 in the invasive carcinoma.
(H) Association between nuclear SLUG and DCIS nuclear grade. *p < 0.05; **p < 0.01; ***p < 0.001 by one-way ANOVA with Tukey’s post
hoc test for comparison between three groups, and Student’s t-test for comparison between two groups. Correlation and P values were
calculated using the Pearson correlation statistic. Error bars represent SD.

Elevated TBX3 levels are associated with poor
prognosis of breast cancer and are highly correlated
with SLUG
To assess the applicability of our findings in a broader
breast cancer and pan-cancer context, we compared our
findings with those of available transcriptomic datasets.

Using the ICGC US donor cohort, we found that TBX3
mRNA levels were elevated in tumor cells of several
cancer subtypes, including breast cancer (data not
shown). By further profiling transcriptomic data from
the TCGA BRCA and the Farmer Breast study [33],
we identified an association of higher TBX3 levels in
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luminal breast cancers, and ER- and PR-positive cancers
(Figure 5A,B). Survival analysis of luminal A patients
in the TCGA BRCA dataset showed a statistically
significant difference in survival (p < 0.001) between
patients with high and low TBX3 relative to the median
(Figure 5C).
To examine the association between TBX3 and our
identified downstream targets SLUG and TWIST1 and
relate it to histopathological grade, we interrogated
transcriptomics datasets with relevant grade information: TCGA BRCA (n = 680 with grade information)
and Desmedt (n = 196, node-negative breast cancers, all
with grade information [34]). TBX3 and SNAI2 mRNA
levels were significantly lower in high-grade breast cancers than in low- and intermediate-grade breast cancers
(Figure 5D) (p < 0.001), consistent with our immunohistochemical data. The Desmedt dataset also showed
reduced TWIST1 levels in high-grade breast cancers.
There was a high degree of overlap between TBX3
and SLUG in terms of patient characteristics and lesion
types identified in our immunohistochemical staining
and within the transcriptomics datasets. Additionally,
upon examination of the TCGA TARGET GTEx dataset,
we observed co-expression of SNAI2 and TBX3 and tight
association of MMP14 with high levels of both transcription factors (Figure 5E). Collectively, analysis of publicly available data further supports the association and
likely involvement of TBX3, along with downstream
EMT transcription factors SLUG and TWIST1, in the
aggressiveness of low-grade breast cancers.

Discussion
The use of screening mammography has drastically
increased our ability to detect DCIS [35], but has
been criticized as causing an overdiagnosis of breast
cancer [36]. Gene expression profiling has allowed
successful stratification of node-negative invasive breast
cancers into low-risk and high-risk groups, providing
information useful in clinical decision-making for this
population [37]. These techniques have been extended
to DCIS with some success [38–40]. Additionally,
panels of selected markers, including p16, COX2, and
Ki67, have shown some utility in their ability to predict
the behavior of DCIS in specific subsets of patients [41].
Despite these efforts, there are few validated diagnostic
tests or biomarkers to aid in optimization of treatment
strategies for women with DCIS, and none that reliably
predict risk for invasion.
We have previously established a role for TBX3 in the
invasiveness of breast cancer [24]. In this current study,
we further explored the mechanism of this activity, particularly as associated with the phenomenon of EMT.
We sought to take a high-resolution approach to identifying downstream targets of TBX3, beginning with
identification of transcriptomic changes with TBX3
overexpression and assessment of direct TBX3 binding
sites. From these initial genomic studies, we identified
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SLUG and TWIST1 as potential downstream effectors
up-regulated with TBX3 overexpression, and SLUG
as a direct downstream mediator of TBX3-induced
migration and invasion. Importantly, we have discerned
expression differences in these proteins between benign
non-columnar ductal epithelial cells, CCLs, DCIS,
and within the invasive carcinoma. Our examination
of TBX3 by immunohistochemistry in two independent patient cohorts revealed that levels are highest
in hormone receptor-positive, low-grade DCIS (and
co-existing CCLs) and are associated with the extent of
invasion in early-stage breast cancers. These findings,
coupled with our in vitro data of an EMT link, are
consistent with a role for TBX3 in early invasion events,
likely working in conjunction with other EMT-related
factors such as SLUG and TWIST1 to facilitate a
phenotype conducive to invasion.
The prevailing breast cancer progression model supported by numerous genomic and transcriptomic studies
includes two divergent molecular pathways of progression – the low-grade (ER+ /PR+ ) and the high-grade
(ER− /PR− ) pathway [23]. Interestingly, sequencing and
hierarchical clustering of DCIS and invasive samples
have shown that samples do not cluster by diagnosis,
but rather by intrinsic molecular subtype [42]. This
suggests that factors associated with invasiveness are
distinct from histologic grade and stage and may indeed
be present within the pre-invasive DCIS [42].
Our proposed model of the stage-specific role of
TBX3 in early breast cancer progression is depicted
in Figure 6. As observed in our immunohistochemical
studies, expression of EMT-related transcription factors (including TBX3) is low in benign non-columnar
breast epithelium. We have identified that TBX3 levels
are significantly elevated in CCLs. This is in accordance
with existing studies examining patterns of gene expression changes through breast cancer progression showing
up-regulation of several malignancy-associated genes at
the pre-invasive stage [43]. This pro-EMT phenotype
in CCLs, with concomitant up-regulation of SLUG and
TWIST1, is predicted to promote proliferation and plasticity of breast epithelial cells [20]. There is accumulating evidence that CCLs, and in particular the CCL
variant termed ‘flat epithelial atypia’ (FEA), may be
non-obligate precursors to the development of breast
cancer [30,31]. Only some CCLs progress, even though
TBX3 and the EMT transcription factors SLUG and
TWIST1 are expressed in most (at least when observed
in association with DCIS). This suggests that there are
likely other changes that act in concert to allow for progression to occur.
In our present study, the significant level of enrichment of proteases, protease inhibitors, and enzyme
modulators in RNA-Seq and ChIP-array datasets of
DCIS-like 21NT cells overexpressing TBX3 is consistent with the propensity to break down basement membrane and invade. Previous studies have suggested that
the gradual loss of basement membrane, leading to
changes in cell organization and polarity (rather than the
acquisition of additional mutations), is the main driver
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Figure 5. Elevated TBX3 levels are associated with poor prognosis of breast cancer and are highly correlated with SLUG expression.
(A, B) TBX3 was assessed across tumor characteristics in the Farmer Breast and TCGA BRCA cohorts. TBX3 mRNA by molecular subtype
was further investigated in the TCGA BRCA dataset. (C) Kaplan–Meier survival curves for luminal A patients (ER+ PR+ HER2− ) from the
TCGA BRCA dataset, separated into high (above median) versus low (below median) TBX3. Number of events (breast cancer-related deaths)
is shown in the associated table. (D) TBX3, SLUG, and TWIST1 in the TCGA BRCA and Desmedt datasets across grades. Data shown represent
median-centered, z-score normalized values. (E) Correlation of SLUG, TBX3, and MMP14 in the TCGA Target GTEx dataset consisting of
19 120 normal and tumor samples. *p < 0.05; **p < 0.01; ***p < 0.001 by one-way ANOVA with Tukey’s post hoc test for comparison between
three groups. Survival analysis for Kaplan–Meier curve was calculated using the log-rank test statistic. Correlation and P values were
calculated using the Pearson correlation statistic. Error bars represent SD.

in the transition from an in situ to an invasive phenotype [44]. We have shown that induction of MMP14
with TBX3 overexpression is a SLUG-dependent process, and this signaling cascade may be important
for TBX3-induced migration and invasion. In keeping
with this, it has been previously reported that MMP14
is among the main regulators of the basement membrane transmigration process in vivo [45], likely due
to MMP14-dependent activation of the main type IV
collagenase MMP2 [46]. Importantly, we have shown
increased activity of MMP2 with TBX3 overexpression.
Additionally, increased expression of several proteases
has been shown to indirectly enhance the activity of
EMT transcription factors, leading to a positive feedback loop [20], potentially resulting in high expression
levels of EMT transcription factors and proteases, as
we have observed both in vitro and in our two patient
cohorts.

In conclusion, we propose a unique pathway in which
TBX3 promotes progression through advancement
of low-grade DCIS to invasive carcinoma (Figure 6).
Our proposed model is particularly relevant in the
non-high-grade, ER-positive pathway of progression.
Overexpression of TBX3 at early pre-invasive stages
(CCL, DCIS) of breast cancer progression, inducing
other molecular regulators of EMT (including SLUG
and TWIST1), acts as an enabler to set the stage for
basement membrane breakdown and invasion into
adjacent stroma. Further validation of our findings in
an independent cohort of stage 0 and stage I breast
cancer patients and comparison with follow-up data
should be conducted in order to assess whether TBX3
expression may provide reliable risk stratification for
patients diagnosed with DCIS, possibly in concert with
multiple biomarkers such as Ki67, p16, COX2, and/or
multi-parameter gene expression assays [40,41]. As
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Figure 6. TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG. Proposed model
through which TBX3 promotes the progression of pre-invasive ductal carcinoma in situ (DCIS) lesions. TBX3 levels are low in benign
non-columnar ductal breast epithelial cells. In columnar cell lesions (CCLs), TBX3 levels are up-regulated, with a concomitant increase
in SLUG and TWIST1. This is predicted to promote proliferation and plasticity of early, pre-invasive lesions. In a subset of low-grade DCIS,
TBX3 expression is particularly high. Overexpression of TBX3 induces altered expression of several proteases and protease inhibitors, leading
to degradation of the basement membrane and priming for early invasion of DCIS into adjacent stroma. These events are facilitated by
TBX3-induced and SLUG-dependent expression of pro-migratory molecules such as MMP14 (membrane-bound), fibronectin (extracellular
matrix), and vimentin (intracellular).

T-box proteins such as TBX3 have been shown to have
detrimental effects with respect to cancer progression
and survival [47], a thorough understanding of the
underlying mechanisms involved is crucial.
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